TY - JOUR
T1 - Hypothetical assessment of efficiency, willingness-to-accept and willingness-to-pay for dengue vaccine and treatment
T2 - a contingent valuation survey in Bangladesh
AU - Kabir, K. M.Ariful
AU - Hagishima, Aya
AU - Tanimoto, Jun
N1 - Funding Information:
This study was partially supported by Grant-in-Aid for Scientific Research from JSPS, Japan, KAKENHI (Grant No. JP 18K18924, JP 19KK0262), the Support Center for Advanced Telecommunications Technology (SCAT), the Research Foundation, the I-O DATA Foundation, and the Foundation for the Fusion of Science and Technology (FOST Foundation) through awards to Professor Tanimoto. We would like to express our gratitude to all of these organizations.
Publisher Copyright:
© 2020 Taylor & Francis Group, LLC.
Copyright:
Copyright 2021 Elsevier B.V., All rights reserved.
PY - 2020
Y1 - 2020
N2 - In 2019, Bangladesh has grappled with a record-breaking surge in dengue fever, experiencing the highest number of dengue cases since the year 2000. Together, the intensification of dengue fever combined with a lack of dengue vaccines and appropriate medicines is expected to further the public and government’s interests in appropriate and potential dengue vaccines to control the epidemic. We considered people’s characteristics, dengue experience, and knowledge to assess their willingness-to-accept (WTA) and willingness-to-pay (WTP) for a hypothetical dengue vaccine and ex-post treatment in Bangladesh (June–July 2019). This study implemented a contingent valuation (CV) method with 3,251 respondents in 10 different locations of Bangladesh. All respondents participated in a hypothetical dengue vaccine scenario consisting of 65% (vaccine A), 80% (vaccine B), and 95% (vaccine C) effectiveness levels with three doses of each vaccine and ex-post dengue treatment. Around 71.2% of respondents were willing to pay for at least one of the hypothetical vaccines: A, B, or C. The average WTPs of the three vaccines amounted to US$ 47.0, US$ 66.0, and US$ 89.0, which were defined as the total cost of the doses necessary to obtain immunity. In Bangladesh, there is a significant demand for low-priced dengue vaccines, which was proven by people’s higher acceptance of vaccination practices. Though dengue vaccines are not yet available in Bangladesh, this study provides significant support that both the government and private sectors should work together to develop a reliable and affordable dengue vaccine.
AB - In 2019, Bangladesh has grappled with a record-breaking surge in dengue fever, experiencing the highest number of dengue cases since the year 2000. Together, the intensification of dengue fever combined with a lack of dengue vaccines and appropriate medicines is expected to further the public and government’s interests in appropriate and potential dengue vaccines to control the epidemic. We considered people’s characteristics, dengue experience, and knowledge to assess their willingness-to-accept (WTA) and willingness-to-pay (WTP) for a hypothetical dengue vaccine and ex-post treatment in Bangladesh (June–July 2019). This study implemented a contingent valuation (CV) method with 3,251 respondents in 10 different locations of Bangladesh. All respondents participated in a hypothetical dengue vaccine scenario consisting of 65% (vaccine A), 80% (vaccine B), and 95% (vaccine C) effectiveness levels with three doses of each vaccine and ex-post dengue treatment. Around 71.2% of respondents were willing to pay for at least one of the hypothetical vaccines: A, B, or C. The average WTPs of the three vaccines amounted to US$ 47.0, US$ 66.0, and US$ 89.0, which were defined as the total cost of the doses necessary to obtain immunity. In Bangladesh, there is a significant demand for low-priced dengue vaccines, which was proven by people’s higher acceptance of vaccination practices. Though dengue vaccines are not yet available in Bangladesh, this study provides significant support that both the government and private sectors should work together to develop a reliable and affordable dengue vaccine.
UR - http://www.scopus.com/inward/record.url?scp=85089742448&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85089742448&partnerID=8YFLogxK
U2 - 10.1080/21645515.2020.1796424
DO - 10.1080/21645515.2020.1796424
M3 - Article
C2 - 32820987
AN - SCOPUS:85089742448
VL - 17
SP - 773
EP - 784
JO - Human Vaccines and Immunotherapeutics
JF - Human Vaccines and Immunotherapeutics
SN - 2164-5515
IS - 3
ER -